Observational studyCancer medicine2026
Retrospective Analysis of HER2 Testing, Treatment Patterns, and Clinical Outcomes in Patients With Locally Advanced or Metastatic NSCLC With HER2 Mutations in France.
Observational study in Cancer medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03848052 (Epidemiological Strategy and Medical Economic), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Epidemiological Strategy and Medical Economic (ESME) Research Program / Academic Real World Data Platform: Evolution of the Therapeutic Care in Lung Cancer in France Since 2015
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundHER2 (ERBB2) gene mutations are associated with poor prognosis in non-small cell lung cancer (NSCLC). It is important to identify patients with HER2-mutant (HER2m) NSCLC, as new targeted treatment options are emerging. However, HER2 testing in clinical practice varies across regions, and real-world data on HER2m NSCLC are limited. PATIENTS AND
methodsThis retrospective study included patients from the Epidemio-Strategy and Medical Economics Lung Cancer database (NCT03848052) diagnosed with locally advanced or metastatic (LAM) NSCLC in France (January 1, 2015-December 31, 2020); patients were followed up until April 1, 2022. Data were extracted on April 2, 2022. Primary objectives were to describe the frequency of HER2 testing and test results. Secondary objectives included describing patient characteristics, treatment patterns, and clinical outcomes (stratified by HER2 testing status/results; landmark analyses were conducted to avoid immortal time bias).
resultsOf 18,069 patients with nonsquamous LAM NSCLC, or squamous LAM NSCLC and no history of smoking, 7530 (41.7%) underwent HER2 testing. Median (interquartile range) time between LAM NSCLC diagnosis and first HER2 test result was 28 days (18-49). Of those tested, 152 (2.0%) had a HER2 mutation (HER2m cohort). In the HER2m cohort, 62.5% (n/N = 85/136) of patients received their first HER2 test result prior to first-line treatment; platinum-based chemotherapy was the most frequently received first-line treatment (52.9%, n/N = 72/136), followed by immunotherapy in the second-line setting (29.2%, n/N = 26/89). At 6-month landmark analysis, median (95% confidence interval) overall survival was 18.6 months (14.3-22.5) in the HER2m cohort.
conclusionsThis real-world study demonstrates the low frequency of HER2 testing and potential poor prognosis for patients diagnosed with LAM HER2m NSCLC in France between 2015 and 2020. Despite the low prevalence of HER2m NSCLC, these data highlight the importance of routine HER2 testing to enable patients with HER2m NSCLC to receive treatments that can improve clinical outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.